EGFR and cancer: Through systematic optimization of the immobilization of antibody molecules and the anti‐fouling strategy of the sensing interface, the sensing platform demonstrates the capability to detect trace amounts of cancer markers, such as MIF, EGFR, and GPC1, within intricate biological media.